Tumour cells apoptosis factor

Drug Profile

Tumour cells apoptosis factor

Alternative Names: 84AA–API 14AA; Nerofe

Latest Information Update: 09 May 2016

Price : $50

At a glance

  • Originator Immune System Key
  • Class Antineoplastics; Cardiovascular therapies; Peptide hormones
  • Mechanism of Action Angiogenesis inhibitors; Apoprotein stimulants; Apoptosis stimulants; Immunomodulators; Interleukin 1 receptor-like 1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Haematological malignancies
  • Discontinued Myocardial infarction

Most Recent Events

  • 01 Mar 2017 Immune System Key plans a phase II trial for Acute myelogenous leukaemia and Myelodysplastic syndromes in Romania(NCT03059615)
  • 09 May 2016 Tumour cells apoptosis factor is still in phase I trials for Solid tumours in Israel
  • 09 May 2016 Tumour cells apoptosis factor is still in preclinical trials for Haematological malignancies in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top